These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Retrospective analysis of skin photosensitivity induced by pirfenidone. Wang C; He Y; Sun W; Wu C; Li Z; Sun L J Clin Pharm Ther; 2022 Feb; 47(2):194-199. PubMed ID: 34655088 [TBL] [Abstract][Full Text] [Related]
6. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107 [TBL] [Abstract][Full Text] [Related]
7. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. van Manen MJG; Birring SS; Vancheri C; Vindigni V; Renzoni E; Russell AM; Wapenaar M; Cottin V; Wijsenbeek MS Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29051272 [TBL] [Abstract][Full Text] [Related]
8. A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis. Anderson A; Shifren A; Nathan SD Expert Opin Drug Saf; 2016 Jul; 15(7):975-82. PubMed ID: 27177012 [TBL] [Abstract][Full Text] [Related]
9. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients. Feng H; Zhao Y; Li Z; Kang J Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705 [TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257 [TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients. Chung MP; Park MS; Oh IJ; Lee HB; Kim YW; Park JS; Uh ST; Kim YS; Jegal Y; Song JW Adv Ther; 2020 May; 37(5):2303-2316. PubMed ID: 32297284 [TBL] [Abstract][Full Text] [Related]
12. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Chaudhuri N; Duck A; Frank R; Holme J; Leonard C Respir Med; 2014 Jan; 108(1):224-6. PubMed ID: 24269005 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis. Nathan SD; Costabel U; Glaspole I; Glassberg MK; Lancaster LH; Lederer DJ; Pereira CA; Trzaskoma B; Morgenthien EA; Limb SL; Wells AU Chest; 2019 Apr; 155(4):712-719. PubMed ID: 30472023 [TBL] [Abstract][Full Text] [Related]
14. [Real-life experience with pirfenidone in idiopathic pulmonary fibrosis]. Yan YJ; Fan YL; Yu SW; Ye Q Zhonghua Jie He He Hu Xi Za Zhi; 2018 May; 41(5):327-332. PubMed ID: 29747274 [No Abstract] [Full Text] [Related]
15. Pirfenidone in idiopathic pulmonary fibrosis. Taniguchi H; Ebina M; Kondoh Y; Ogura T; Azuma A; Suga M; Taguchi Y; Takahashi H; Nakata K; Sato A; Takeuchi M; Raghu G; Kudoh S; Nukiwa T; Eur Respir J; 2010 Apr; 35(4):821-9. PubMed ID: 19996196 [TBL] [Abstract][Full Text] [Related]
16. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP). Costabel U; Albera C; Lancaster LH; Lin CY; Hormel P; Hulter HN; Noble PW Respiration; 2017; 94(5):408-415. PubMed ID: 28898890 [TBL] [Abstract][Full Text] [Related]
17. Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient? Hayton C; Chaudhuri N Drugs Aging; 2017 Sep; 34(9):647-653. PubMed ID: 28861727 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis. Yoon HY; Kim DS; Song JW Respiration; 2019; 97(3):242-251. PubMed ID: 30332670 [TBL] [Abstract][Full Text] [Related]
19. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM; Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362 [TBL] [Abstract][Full Text] [Related]
20. Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice. Fang C; Huang H; Guo J; Ferianc M; Xu Z PLoS One; 2020; 15(1):e0228390. PubMed ID: 31999801 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]